| INTRODUCTION
The incidence of malignant melanoma is increasing. While surgical resection can be curative, particularly for early disease, Stage III disease with macroscopic (clinically detectable) lymph node involvementhasapoorprognosis,witha5-yearoverallsurvival(OS) rateof29%-51%. 1, 2 There are few adjuvant treatment options for resected Stage III melanoma; interferon alpha and pegylated interferonalphamodestlyextenddisease-freesurvival(DFS),buthave limited effect on OS and may be associated with substantial toxicity. 3, 4 Patientselectionforinterferontherapyrequirescarefulconsideration of the individual's likely benefit and risk, and may also be influenced by physician experience with the product and cost
considerations. Therefore, its use may differ between centres or countries.
Inmanycountries,accesstonewandpotentiallyexpensivetreatments may be influenced by health technology assessment (HTA), which commonly evaluates whether the benefit offered by a medicine isworth its cost. Evidence of the treatment's effect on patient outcomes,includingsurvival,usuallycomesfromclinicaltrials.Inaddition toclinicaltrialdata,high-quality,country-specificreal-worlddatathat describe current treatment patterns, outcomes, resource utilisation andcostsinroutineclinicalpractice,arevaluableintheHTAandreimbursementdecision-makingprocess.Formalignantmelanoma,such data are scarce, especially for small subgroups of patients (ie, Stage IIIB/IIIC).
5-7
Therefore, we conducted an observational burden-ofillnessstudyinFrance,GermanyandUK.Wecollectedreal-worlddata on treatment patterns and healthcare resource use among patients with Stage IIIB/IIIC melanoma with macroscopic lymph node involvement,whoseprimarymelanomaandregionallymphnodemetastases had been completely resected.
| METHODS
This retrospective study was conducted in 49 specialist cancer centres,tertiaryreferralcentres(14inFrance,17inGermany,18inthe UK)selectedtoprovidearangeofgeographiclocations,sizesandinstitutiontypes.Ethicscommitteeapprovalsandstudydesigndetails are provided in Data S1.
Medical records in each centre were screened for patients pre- 
| Study variables
Information extracted from medical records included patient de- Amongpatientsreceivinghigh-doseinterferon,one-third haddosedelaysand/orreductionsandmorethanaquarter discontinued therapy due to toxicity.
• The modest survival benefit and potential toxicity of interferon therapy may contribute to its apparently low level of use.
• Our findings indicate there is an important unmet need to develop more effective and broadly applicable treatments to prevent recurrence and improve survival in this group of patients.
employmentstatus.Patientswereaskedtorecallinformationover theprevious3months,exceptforhospitalisationsandchangesin employment status, which could be reported regardless of when they occurred. Quality life was measured using the EQ-5D questionnaire (three-level version), and using the UK tariff (scoring algorithm)tocalculateutilityscoresfromhealthstatusdatacollected in all countries.
| Analysis and data quality checks
Results were generated by country as descriptive summaries and no 
| RESULTS

| Patient and disease characteristics
Of 917 patients screened for eligibility, 559 met inclusion/exclusion criteria and medical record abstraction was completed for 558 
| Survival outcomes
| Quality of Life and employment status
The mean (95% CI) health utility weight estimates based on the EQ- 
| DISCUSSION
We used a combination of medical record data abstraction and a patient survey to describe the burden-of-illness, current treatment 
T A B L E 2 Clinical and disease characteristics
The baseline characteristics of patients in our study were consistentwithpopulationsofpatientswithStageIIImelanomaintheUSA andEurope 2,9 ;however,withpatientsmorefrequentlybeingyounger than 65 years of age and male.
There appeared to be regional differences in tumour staging methods,with imaging (with/without palpation) to determine lymph node status; FNA cytology was conducted more frequently in the UK, whereas sentinel node biopsy was more common in Germany.
Somewhat fewer patients were diagnosed with extra-capsular node extension in Germany than the other countries, although the use of lymphnodeimagingmethodswassimilarinFranceandGermany.There were also suggestions of regional differences in the use of adjuvant therapy, with a greater proportion of patients in Germany receiving adjuvant therapy, than in France, or the UK. Low-or intermediatedose interferon was used more widely than the high-dose regimen;
and dose reduction, delay and discontinuation due to toxicity were common,reflectingthetoxicityofinterferontherapy.Theobservation that dosing regimens for interferon varies widely is consistent with the lackofconvincingevidencefavouringoneoranotherregimen. 
